Share on StockTwits

Questcor Pharmaceuticals (NASDAQ:QCOR) Insider Don M. Bailey unloaded 40,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $91.96, for a total value of $3,678,400.00. Following the completion of the sale, the insider now directly owns 140,437 shares of the company’s stock, valued at approximately $12,914,587. The transaction was disclosed in a filing with the SEC, which is available at this link.

Questcor Pharmaceuticals (NASDAQ:QCOR) remained flat at $93.60 during during mid-day trading trading on Friday. Questcor Pharmaceuticals has a 52-week low of $47.71 and a 52-week high of $97.80. The stock has a 50-day moving average of $92.90 and a 200-day moving average of $81.15. The company has a market cap of $5.587 billion and a price-to-earnings ratio of 16.41.

Questcor Pharmaceuticals (NASDAQ:QCOR) last posted its quarterly earnings results on Thursday, July 24th. The company reported $1.85 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.74 by $0.11. The company had revenue of $278.80 million for the quarter, compared to the consensus estimate of $261.02 million. During the same quarter last year, the company posted $1.12 earnings per share. Questcor Pharmaceuticals’s revenue was up 38.5% compared to the same quarter last year. On average, analysts predict that Questcor Pharmaceuticals will post $6.73 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on QCOR shares. Analysts at Oppenheimer downgraded shares of Questcor Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, July 25th. They now have a $86.00 price target on the stock. Analysts at Mizuho downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, May 19th. They now have a $92.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $84.44.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.